I Gave My Cardiologist a Heart Attack
In this hour‑long monologue, Harvard‑ and Oxford‑trained MD‑PhD Nick Norwitz reveals that his LDL cholesterol is 574 mg/dL and total cholesterol exceeds 700 mg/dL, yet he remains asymptomatic. He explains that his extreme lipid profile is not due to familial hypercholesterolemia but to a metabolic phenotype he calls the Lean‑Mass Hyperresponder (LMHR), which commonly appears in lean, insulin‑sensitive individuals on very low‑carbohydrate (ketogenic) diets. He defines the LMHR phenotype (LDL > 200 mg/dL, HDL > 80 mg/dL, triglycerides < 70 mg/dL), discusses the lipid‑energy model that links rapid fat mobilization, VLDL turnover, and elevated LDL/HDL, and reviews supporting evidence: a meta‑analysis of 41 RCTs, clinical observations of LDL spikes as BMI falls below ~25, and a case study of a diabetic patient whose LDL doubled after weight loss. Norwitz describes his own n=1 crossover trial – “Oreo versus Statin” – where adding 12 Oreo cookies daily to his ketogenic diet lowered LDL more than a 6‑week course of 20 mg Crestor, detailing IRB exemption, lab ordering, and co‑author collaboration. He emphasizes that LDL alone does not predict plaque progression; instead, coronary artery calcium (CAC) scores and CT angiography are more reliable, noting his own CT shows no plaque despite the high LDL. He explains his current decision to avoid statins, citing lack of evidence for benefit in LMHRs, potential drug risks, and his plan to test ezetimibe and bempedoic acid in future self‑experiments. Throughout, he stresses scientific openness, invites critique, and provides extensive resources (keto‑CTA study, Dave Feldman presentation, etc.). The video’s purpose is to educate newcomers about LMHR biology, the controversy surrounding it, and the personal decision‑making process behind living with extreme LDL levels.
Chapters
All right, I have a confession to make. As a Harvard and Oxford-trained MD-PhD, I'm walking around with an LDL cholesterol over 500. 574 on last check. And my total cholesterol's over 700. Now, to put these numbers in perspective, if you show them to your average doctor, they can't believe them. They're higher than levels your average doctor sees in their entire career. You show them to a cardiologist and they're astounded I'm even walking around alive, let alone thriving. Because these levels, they rival those found in a 1 in 1 million genetic condition: homozygous familial hypercholesterolemia, a disease that kills children by heart attacks by as young as 8 or 10. A disease that has cemented a fear of LDL into the bedrock of modern cardiology. But here's the thing. I don't have familial hypercholesterolemia. Something very different, something very misunderstood is going on inside my body. And in today's video, I want to talk to you about it. I want to bring you to the bleeding edge of modern cardiology, lipidology, and metabolism. Talk about difficult medical decisions that I've had to make personally. I'm going to disclose a lot, but I want you to really hear the words that are coming out of my mouth. You'll realize this isn't about dogma. This isn't about what to think. This is about how to think. Let's get started. We actually have very strong evidence for— it tends to work predictably and reliably. Are lean mass hyperresponders at high risk for cardiovascular disease? The leanness isn't a fixed rule. I agonized over it. The Oreo cookies lowered my LDL more than twice as much as the statin. This response is now recognized as a distinct metabolic phenotype. This is a controversial question, and the answer is: lean mass hyperresponders are far more interesting. Look at your LDL and ApoB levels in context. Anyway, once my doctors recover from their metaphorical surprise-induced myocardial infarction, their fear turns to confusion. They wonder, "How could a Harvard Oxford-trained MD PhD be walking around with an LDL of 574 unmedicated?" I once even had someone tell me, and I swear this is a real quote, "I feel like I just saw Albert Einstein snorting lines in a flat earther t-shirt." I guess it's a compliment? Anyway, then their confusion— remember fear to confusion— turns to disbelief when I explain not only do I understand how to lower my LDL cholesterol, I could drop it from 574 to 90 milligrams per deciliter within a few weeks, even without medication. And that's because my LDL is not elevated because of a genetic defect, but because of a different reason. I'm ketogenic, I'm on a ketogenic diet, and I'm lean. In fact, this is a known phenomenon. Lean individuals on ketogenic diets often see dramatic increases in cholesterol—total and LDL cholesterol. Now, to be clear, this is not a majority response. Most people, the majority who go on low-carb diets, are overweight or have obesity. And in those cases, LDL cholesterol and ApoB levels typically stay the same or drop. And real quickly, if that term ApoB is new to you, it's another biomarker that's associated with LDL cholesterol. So cholesterol is a molecule that can be carried around in the blood on various particles. One of these species of particles are LDL particles. LDL cholesterol is the measure or calculation of the cholesterol in all your LDL particles, and ApoB is an apolipoprotein on each LDL particle. There's one ApoB per one LDL. And if that went over your head, don't worry about it. The point is this: that among lean insulin-sensitive individuals, cholesterol—LDL cholesterol and ApoB—can rise astronomically when people go low-carb. This response is now recognized as a distinct metabolic phenotype known as the lean mass hyperresponder, or LMHR. My colleagues and I have been studying lean mass hyperresponders for years, trying to understand what they are, why they respond this way and what their true cardiovascular risk profile might be. And yes, as many of you know, the research has become a lightning rod for controversy on social media. But if you think that bothers me, it doesn't. It excites me, at least from a scientific perspective. Yes, my numbers and those like me are extreme, and I've never claimed to be entirely comfortable with them or know with certainty that My condition is safe. I've never made that claim. But the curiosity, the confusion, the skepticism, even the reflexive anger, often an emotion of ignorance. I've seen this from the general public, physicians, academics, and what it tells me, it's actually social data for me. It tells me we're asking the right questions. In fact, if you'll indulge me in a little personal family history disclosure, my dad, Give me a hand to climb down the stairs. Oh, you're a big boy, you can do it by yourself. And who was a bit of a troublemaker himself in his own right, he always encouraged me as a child to keep asking questions. I'm really grateful for this lesson. He always taught me, if you're not satisfied with an answer, don't fold to authority, not even me, me being dad, keep asking. And if the authority gets pissed off and fails to provide sufficient answers still, it probably means you don't just have a good question, you have a great question. Never let your curiosity be bullied into submission. Anyway, in this video, my goal is to explain to you what lean mass hyperresponders are, bring you up to speed on the what, why, and how of this phenotype, and to clarify why I'm willingly walking around with an LDL cholesterol of 574 mg/dL, and why I don't recommend you generalize from my n=1 to your own. And I'm going to direct you to more learning resources by the end. Anyway, lean mass hyperresponders— let's define them. They're individuals who adopt a low-carbohydrate diet, often ketogenic, and then experience a change in their lipid profile. Their LDL jumps to over 200 mg/dL, their HDL also jumps over 80, and their triglyceride cholesterides are 70 or below. Now this lipid profile is rare in the general population, but surprisingly common among lean individuals who go low-carb. And to be clear, people get confused about this, lean isn't actually a criterion. The term lean mass in lean mass hyperresponder reflects the hypothesis that this pattern, this lipid pattern I just described emerges in those who are lean, insulin sensitive, and on low-carb diets. The leanness isn't a fixed rule, but a metabolic fingerprint. It's kind of like a party trick where I can go, or my friends can go, to a group, say a gym, and look around and pick people out who we think could convert into lean mass hyperresponders because they look a certain way. And importantly, really importantly, this lean mass hyperresponder phenomenon must be distinguished from what I mentioned earlier, familial hypercholesterolemia, where LDL cholesterol and ApoB levels are high from birth due to a genetic defect in lipid metabolism, a broken lipid metabolism. By contrast, lean mass hyperresponders like me have generally normal cholesterol on mixed macronutrient diets, and only see their LDL cholesterol surge when they restrict carbohydrates. And as an added nuance note, this isn't a result of just saturated fat, butter guzzling, or a fiber deficiency either. Lean mass hyperresponders are far more interesting, In fact, I can actually eat a very low saturated fat, high fiber diet, but if my carbs are low, my LDL is high, much higher than if I eat a standard American diet, even filled with cookies and ice cream. In fact, to demonstrate how unique this phenotype is, how unusual it is, I ran a rather famous experiment. Many of you might know about it, it was called Oreo versus Statin, but let's review for those of you who have not heard about it. Over a year ago, I predicted, then publicly stated that I could lower my LDL cholesterol by eating 12 Oreo cookies per day on top of an otherwise ketogenic diet. That's about 100 grams of net carbs daily added to my diet. I hypothesized this would be sufficient to drop my LDL. Now, to be clear, this wasn't a dietary swap, it was a pure addition. I kept strictly to my baseline diet, but added a sleeve of Oreos per day. But I didn't just stop there. As a scientist, I tried to dot my i's and cross my t's. So I submitted the protocol to Harvard's Institutional Review Board, received an IRB exemption letter, and had my primary care physician order all labs directly into my electronic medical record, and recruited a senior lipidologist—maybe you guys know Dr. William Cromwell—to consult and co-author what would become a peer-reviewed and published case study. The famous Oreo versus statin study. So this is how the trial was conducted. It was a crossover trial. First, I had the cookie intervention. After locking in my baseline diet, I ate Oreo cookies on top of that diet for about 2 weeks. Then I engaged in a 3-month washout period to reset my cholesterol. And then I underwent 6 weeks of high-intensity statin therapy, 20mg of Crestor daily. The results? The Oreo cookies lowered my LDL more than twice as much as the statin, and in one-third the time. And even though this was an n=1 experiment, the results were predictable, robust, widely shared, and have since been replicated by half a dozen or more MDs and PhDs. In fact, my only regret on this project is that I didn't end the paper, "And that's how the cholesterol cookie crumbles." Now, to be clear, I'm not recommending this intervention, I'm not recommending Oreo cookies for health. The result is interesting, and it's meant to be a metabolic demonstration specific to the metabolic context of lean, insulin-sensitive individuals who go on low-carb or ketogenic diets. It wouldn't apply to your average person eating a standard Western diet. So for those of you watching this really eager to add an Oreo milkshake to your standard lunch of burger and fries, I'm sorry, it won't work. But for those, like me, it tends to work predictably and reliably. And no, it doesn't need to be Oreos, it can be any carb, any carbohydrate source in a lean mass hyperresponder, a true lean mass hyperresponder will drop their LDL cholesterol. So why? Let's get to that explanation. The lipid energy model is what explains the lean mass hyperresponder phenotype. It proposes that when you're lean and insulin sensitive, going low carb increases fat burning—fat mobilization. Free fatty acids are released from your fat cells into the bloodstream, and some are taken up by the liver where they are repackaged into what are called VLDL particles. These are precursors to LDL particles. These VLDLs, they don't build up because they're rapidly offloaded at muscle and fat tissue. Otherwise stated, there's rapid turnover of the VLDL particles, and this results in elevated LDL, elevated HDL, and lower triglycerides. If you want more on this, you can read this paper. And while the lipid energy model is still a hypothesis, it continues to predict outcomes remarkably well again and again and again across individuals and across interventions. So it's the best working model we have, and we're continuing to work to develop it. And here's the rub, chub. You might be wondering now, why does this just happen in lean people? Why doesn't the lipid energy model apply to those in obesity? Why is it revealed by leanness? Well, we don't really know, at least not completely, but we do know a few things. First, lean insulin-sensitive individuals, they tend to ramp up fat metabolism far more effectively than those with obesity, when carb restricted. Second, fat is an endocrine organ. It secretes hormones like leptin, adiponectin, 12,13-DiHOME, myeloperoxidase, and others. And this shifts metabolic dynamics broadly. These hormones likely collectively influence whether someone becomes a lean mass hyperresponder or not. And I'd also add that everyone has a different personal fat threshold where they retain fat, how big their fat cells grow. So what that means is that for some people, a lean mass hyper-responder phenotype, that metabolic triad of lipid markers, might show up below a BMI of 27, for others below a BMI of 22. And some people may never become lean mass hyper-responders no matter how lean they get. It's possible. So while this is not a primary genetic condition, there may be permissive or restrictive genetics that allow the phenotype. That's possible. Third, we actually have very strong evidence for an inverse relationship between LDL cholesterol and BMI, consistent with the lipid-energy model. To be clear, this is in the context of low-carb diets. But around the same time as the Oreo versus statin paper was published, we also published another study, a meta-analysis of 41 human randomized controlled trials in a top nutrition journal the American Journal of Clinical Nutrition, and it showed that the leaner you are, the greater your LDL cholesterol rises on low-carb diets. Now, if you respect the hierarchy of evidence, it doesn't get much stronger than a meta-analysis of human randomized controlled trials. And fourth, clinicians are seeing these patterns too. Many patients' LDL cholesterol stay flat or decline as they lose weight, if they have excess weight to lose, on ketogenic diets. —until they reach a BMI around 25. Then the LDL can spike sharply. There are numerous examples, but here's one real example I have permission to share. My colleague and co-author on many of these projects, Dr. Professor Adrian Sotomayor, MD, PhD, cared for a 60-year-old male patient with type 2 diabetes. The patient adopted a ketogenic diet and his BMI steadily decreased from 29.5 to 24.5. And during his weight loss journey, his LDL remained lowish, around 90, 95, until he reached that healthy BMI, under 25. Then his LDL jumped and more than doubled to 183.4. Shocking, isn't it? I guess bye-bye belly, hello ApoB. So now, the big question: are lean mass hyperresponders like me at high risk for cardiovascular disease? This is a controversial question, and the answer is yes and no. Lean mass hyperresponders don't have a uniform risk profile. Some do show plaque progression, others show no plaque progression, and some even show regression— plaque regression. Yes, this has been confirmed, and if you want to see more on that, see this video. But what is really key is that this variability in plaque progression does not appear to track with the usual suspect—LDL or ApoB levels. Instead, it correlates with pre-existing plaque, which can be detected using tools like coronary artery calcium scans, or CAC scans. Coronary plaque, once it's present, tends to feed forward—it snowballs. And that doesn't mean progression can't be stopped or even reversed, but it does mean that LDL cholesterol alone doesn't give a full picture. So if you're serious about addressing your risk, you need to broaden the aperture of your view. Look at CAC scores or more advanced imaging like coronary CT angiography—that's what I've gotten for myself. And even independent of cardiac imaging, you need your doctor—you and your doctor—to look at your LDL and ApoB levels in context. As any well-informed and learned endocrinologist—a hormone doctor—will tell you, There's no "normal" when it comes to a hormone, just appropriate and inappropriate for the context. A single red or out-of-range marker on a lab report can be tremendously misleading when not interpreted in the context of other markers and the patient's individual personal medical history. And on the matter of cardiac imaging like CAC scores, it's not even controversial science anymore. It's showing up in many mainstream cardiology journals. CAC scores are far better predictors of cardiovascular events than LDL and cholesterol. And if you want more on the science of CACs, you can see this video, totally dedicated to how to interpret CACs. Now, I know many of you who have been following the keto-CTA drama would crucify me on a cross made of test tubes if I failed to address this study. I'm not hiding on this matter, but there's so much to unpack it's beyond the scope of this video. The purpose of this video is to get newbies up to speed on this area of research and explain why my own case is the way it is and why I'm actually willing to stroll around Boston with an LDL of near 600. But if you do want more on the keto-CTA study, we are now speaking up, so start by seeing Dave Feldman's presentation and also our recent interview. Hey, this doesn't make sense to me. This is the hardest I've ever had to work at I'm not running my mouth. These and many more resources are linked below. This study, and this story, are quickly evolving. It's certainly been a drama, a pretty exciting one at that. But let me bring this back to my own story, because I know it's of interest to many of you. Let's face it, a Harvard Oxford-trained MD-PhD walking around with an LDL of 574 is going to raise some big eyebrows. I got caterpillars up here. And, Since I've chosen to be radically open about my personal health journey—this was a decision I made early on in my public life—I do feel an obligation to explain why I've made the choices I've made, and why I do not expect you to do the same. First and foremost, this is not a casual decision for me. I agonized over it. Strike that. I do agonize over it. Present tense. My position is not cemented. I'm open to changing my opinion as new data emerge. And if a lipidologist or any celebrity scientist wants to challenge me on the record, on a recorded podcast or a livecast, I welcome it. I will eat my pride if the evidence is compelling. Because whether or not you think I have ego wrapped up in the results of our studies and am thereby biased in my interpretation of the data, I think you'd have a hard time making the case that I'm outright stupid. And only a truly stupid person will put ego before his own life. So why am I not taking a statin or other cholesterol-lowering medication? Because quite honestly, I'm not convinced it would benefit me. The data for lipid-lowering medications improving outcomes in people like me who are lean, insulin sensitive, and lean mass hyperresponders on ketogenic diets is entirely nonexistent. And generalizing from one population to another is reaching. That's Biomedicine 101. You don't generalize from population A to population B if you can help it. So you can say preponderance of evidence all day long, but if the preponderance of evidence wasn't collected in populations like me, it's not all that relevant. And yeah, statins and medications like them, they carry risks. Some known—see this video—and others less understood or not understood. But for me, instead of medicating as the default, I've chosen to just track my own plaque status using imaging. So far, my coronary CT angiography shows no plaque, calcified or otherwise. Now admittedly, I'm just shy of 30, but with LDL cholesterol as high as mine, 574, many would expect measurable disease. Honestly, if I had homozygous familial hypercholesterolemia, I'd probably be dead. And yet, to date, my arteries are as clean as a whistle. If that changes, I will act. And I'll tell you, but I'm not ready to sign up to take a drug for life that might not help me, nor abandon the ketogenic diet that saved my life from inflammatory bowel disease. And that's not hyperbole. If you know my story, you know I'm not exaggerating. I wanted to interject momentarily. As you can imagine, I thought about this video in composing it, then I sat on it for months before eventually deciding to Release it. Now we're in final edit and I'm just looking back at it and I thought I'd actually disclose an experiment that I want to do on myself, a crossover experiment with two different medications, not statins. I have my concerns about statins and PCSK9 inhibitors, but ezetimibe and also bempedoic acid. My understanding of their mechanism suggests to me that they're less likely to have negative effects on muscle, brain, and mitochondrial health and overall metabolic health. So I'm collecting data on myself to see how these medications impact me at this This is an ever-evolving discussion. I am talking with experts in the field to get their perspectives. I'm not shut down on this. I'm not flipping about it. Yeah, maybe I have my biases, but my primary bias is to not die. So this will be an ongoing discussion, but you should just know that I am open to talking with my doctors about different options. Right now I am not medicated, but that's subject to change. So I will come out with more details on this protocol, what I'm measuring, why I'm measuring it. And you can check out the newsletter link below for more information. Thanks. So critique my choices if you want. I've opened the door to that. I've opened the door to feedback and I welcome it. Let me be clear, my goal here is not to be the mascot for the LDL denier cult counterculture. My goal is to make the most informed decision I can for me and help others learn to do the same. And right now I have to make decisions with incomplete and imperfect data. That's suboptimal. It's also reality. So what is my purpose here? It's not to say, do as I do. It's not to be your heart health guru. It's not to tell you that your cardiologist is wrong. It's not to tell you that ApoB doesn't matter. My purpose is to bring more authenticity and curiosity to this space. It desperately needs it. I won't pretend my messaging has been perfect. It wasn't. It won't ever be, but I care. I hope you believe that and that I'm trying, and I promise you I will continue to try until the day I die. Whether that's at 120 or at 35, if I'm really wrong. And yeah, I'm putting myself out there. And yeah, that invites criticism. So to the haters, I say, do your worst, because I've noticed something. The more people attack in ignorance, the more attention this research gets, the more attention it gets, the more opportunities we have for funding, for collaboration, and for discovery. And if I have to take a few arrows in the back to move this forward, So be it. I invite it. And finally, if you really want more information on cardiovascular disease and metabolic health, I've linked a mountain of resources below, and it's only getting bigger. But one thing I promise you, if you engage with me here and elsewhere, you'll never be starved of thoughtful, evolving content. Stay curious, stay skeptical, stay an independent thinker. I hope this made sense to you.
